{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:26:43Z","timestamp":1776936403898,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009075","name":"Bankhead-Coley Foundation","doi-asserted-by":"publisher","award":["23B15"],"award-info":[{"award-number":["23B15"]}],"id":[{"id":"10.13039\/100009075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009075","name":"Bankhead-Coley Foundation","doi-asserted-by":"publisher","award":["23B15"],"award-info":[{"award-number":["23B15"]}],"id":[{"id":"10.13039\/100009075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009075","name":"Bankhead-Coley Foundation","doi-asserted-by":"publisher","award":["23B15"],"award-info":[{"award-number":["23B15"]}],"id":[{"id":"10.13039\/100009075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Melanoma brain metastases (MBM) are a leading cause of death in patients with advanced disease. MBM treatment relay on targeted and immunotherapy and on stereotactic radiosurgery as gold standard. Life expectancy has improved significantly with these therapies however, targeted therapy is short lived and only about half of the patients respond to immunotherapy, while radiation is limited by melanoma cells intrinsic resistance to DNA damage. New therapeutic approaches are therefore needed to treat MBM. Here we investigate a new role of Notch1 in genomic instability and demonstrate that blockade of both Notch1 and the DNA repair factor ChK1 causes extensive DNA damage and tumor cell death increasing survival in MBM bearing mice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Anti-Notch1 (anti-N1) was previously described. Prexaserib, a ChK1 inhibitor, is currently in clinical trials. K457 and A375 melanoma cells were used. RNA sequencing was performed in K457 cells treated with anti-N1 and Gene Set Enrichment Analysis performed. DNA damage was evaluated by a DNA fiber assay to assess replication fork speed; and \u03b3H2AX foci count and neutral comet assay to quantify double strand breaks. Cell survival was evaluated by trypan blue and a colony formation assay. Luciferase expressing A375 cells were orthotopically inoculated in the right cerebral cortex of athymic nude mice, for in vivo evaluation of a therapy with anti-N1 and prexasertib. Survival was assessed by Kaplan-Meyer survival curves and significance assessed by a Log-rank test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Notch1 blockade caused genomic instability by reducing histone availability, leading to DNA replication stress and DNA damage. This in turn, resulted in the activation of the DNA Damage Response pathway ATR\/ChK1 to counter the damage. Co-inhibition of Notch1, via anti-N1, and ChK1, via prexasertib (prex), exacerbated DNA damage increasing melanoma cell death. Importantly, combination anti-N1\/prex significantly improved survival of mice bearing MBMs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A therapy with anti-N1\/prexasertib could represent a novel treatment strategy, alone or in combination with current treatment regimens, for melanoma brain metastases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03411-w","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T03:05:57Z","timestamp":1748401557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Co-inhibition of Notch1 and ChK1 triggers genomic instability and melanoma cell death increasing the lifespan of mice bearing melanoma brain metastasis"],"prefix":"10.1186","volume":"44","author":[{"given":"Varsha","family":"Thakur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay S.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dazhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliano Tiburcio","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Alberto","family":"Nivelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Umland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M.","family":"Welford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Bedogni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"3","key":"3411_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2478\/raon-2022-0032","volume":"56","author":"JF Thompson","year":"2022","unstructured":"Thompson JF, Williams GJ, Hong AM. Radiation therapy for melanoma brain metastases: a systematic review. Radiol Oncol. 2022;56(3):267\u201384.","journal-title":"Radiol Oncol"},{"issue":"5","key":"3411_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022;40(5):492\u2013516.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3411_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631\u20139.","journal-title":"Ann Oncol"},{"issue":"7","key":"3411_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863\u201373.","journal-title":"Lancet Oncol"},{"key":"3411_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/EDBK_200819","volume":"38","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Boutros C, Kok D, Robert C, McArthur G. New era in the management of melanoma brain metastases. Am Soc Clin Oncol Educ Book. 2018;38:741\u201350.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"3411_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672\u201381.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3411_CR7","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1038\/jid.2008.289","volume":"128","author":"M Osawa","year":"2008","unstructured":"Osawa M, Fisher DE. Notch and melanocytes: diverse outcomes from a single signal. J Invest Dermatol. 2008;128(11):2571\u20134.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"3411_CR8","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1172\/JCI36157","volume":"118","author":"B Bedogni","year":"2008","unstructured":"Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest. 2008;118(11):3660\u201370.","journal-title":"J Clin Invest"},{"issue":"43","key":"3411_CR9","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1038\/onc.2011.606","volume":"31","author":"K Zhang","year":"2012","unstructured":"Zhang K, Wong P, Zhang L, Jacobs B, Borden EC, Aster JC, Bedogni B. A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene. 2012;31(43):4609\u201318.","journal-title":"Oncogene"},{"issue":"11","key":"3411_CR10","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1172\/JCI25001","volume":"115","author":"K Balint","year":"2005","unstructured":"Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco AJ, Herlyn M, Liu ZJ. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest. 2005;115(11):3166\u201376.","journal-title":"J Clin Invest"},{"issue":"8","key":"3411_CR11","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1158\/0008-5472.CAN-05-3589","volume":"66","author":"ZJ Liu","year":"2006","unstructured":"Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase\/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 2006;66(8):4182\u201390.","journal-title":"Cancer Res"},{"issue":"13","key":"3411_CR12","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1158\/0008-5472.CAN-08-3767","volume":"69","author":"CC Pinnix","year":"2009","unstructured":"Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009;69(13):5312\u201320.","journal-title":"Cancer Res"},{"issue":"2","key":"3411_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jid.2015.11.006","volume":"136","author":"K Zhang","year":"2016","unstructured":"Zhang K, Wong P, Salvaggio C, Salhi A, Osman I, Bedogni B. Synchronized targeting of Notch and ERBB signaling suppresses melanoma tumor growth through inhibition of Notch1 and ERBB3. J Invest Dermatol. 2016;136(2):464\u201372.","journal-title":"J Invest Dermatol"},{"key":"3411_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.canlet.2018.07.024","volume":"434","author":"H Qiu","year":"2018","unstructured":"Qiu H, Zmina PM, Huang AY, Askew D, Bedogni B. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties. Cancer Lett. 2018;434:144\u201351.","journal-title":"Cancer Lett"},{"issue":"1","key":"3411_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13046-024-03214-5","volume":"43","author":"JT de Freitas","year":"2024","unstructured":"de Freitas JT, Thakur V, LaPorte KM, Thakur VS, Flores B, Caicedo V, Ajaegbu CGE, Ingrasci G, Lipman ZM, Zhang K, et al. Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME. J Exp Clin Cancer Res. 2024;43(1):295.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"3411_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ygyno.2022.09.019","volume":"167","author":"PA Konstantinopoulos","year":"2022","unstructured":"Konstantinopoulos PA, Lee JM, Gao B, Miller R, Lee JY, Colombo N, Vergote I, Credille KM, Young SR, McNeely S, et al. A phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecol Oncol. 2022;167(2):213\u201325.","journal-title":"Gynecol Oncol."},{"issue":"5","key":"3411_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11523-021-00835-0","volume":"16","author":"KN Moore","year":"2021","unstructured":"Moore KN, Hong DS, Patel MR, Pant S, Ulahannan SV, Jones S, Meric-Bernstam F, Wang JS, Aljumaily R, Hamilton EP, et al. A phase 1b trial of prexasertib in combination with standard-of-care agents in advanced or metastatic cancer. Target Oncol. 2021;16(5):569\u201389.","journal-title":"Target Oncol"},{"issue":"9","key":"3411_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29065","volume":"68","author":"T Cash","year":"2021","unstructured":"Cash T, Fox E, Liu X, Minard CG, Reid JM, Scheck AC, Weigel BJ, Wetmore C. A phase 1 study of prexasertib (LY2606368), a CHK1\/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: a report from the Children\u2019s Oncology Group pediatric early phase clinical trials network (ADVL1515). Pediatr Blood Cancer. 2021;68(9): e29065.","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"3411_CR19","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1158\/1078-0432.CCR-19-2773","volume":"26","author":"C Marusak","year":"2020","unstructured":"Marusak C, Thakur V, Li Y, Freitas JT, Zmina P, Thakur VS, Chang M, Gao M, Tan J, Xiao M, et al. Targeting extracellular matrix remodeling restores BRAF inhibitor sensitivity in BRAFi resistant melanoma. Clin Cancer Res. 2020;26(22):6039\u201350.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"3411_CR20","first-page":"vdac147","volume":"4","author":"V Thakur","year":"2022","unstructured":"Thakur V, Thakur VS, Aguila B, Slepak TI, Wang M, Song W, Konai M, Mobashery S, Chang M, Rana AB, et al. Targeting extracellular matrix remodeling sensitizes glioblastoma to ionizing radiation. Neurooncol Adv. 2022;4(1):vdac147.","journal-title":"Neurooncol Adv"},{"issue":"7","key":"3411_CR21","doi-asserted-by":"publisher","first-page":"e0253062","DOI":"10.1371\/journal.pone.0253062","volume":"16","author":"V Thakur","year":"2021","unstructured":"Thakur V, Tiburcio de Freitas J, Li Y, Zhang K, Savadelis A, Bedogni B. MT1-MMP-dependent ECM processing regulates laminB1 stability and mediates replication fork restart. PLoS One. 2021;16(7):e0253062.","journal-title":"PLoS One"},{"issue":"1","key":"3411_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"issue":"1","key":"3411_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12859-018-2486-6","volume":"19","author":"SX Ge","year":"2018","unstructured":"Ge SX, Son EW, Yao R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics. 2018;19(1):534.","journal-title":"BMC Bioinformatics"},{"issue":"15","key":"3411_CR24","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1158\/1078-0432.CCR-16-2876","volume":"23","author":"CD Lowery","year":"2017","unstructured":"Lowery CD, VanWye AB, Dowless M, Blosser W, Falcon BL, Stewart J, Stephens J, Beckmann RP, Bence Lin A, Stancato LF. The checkpoint kinase 1 inhibitor prexasertib induces regression of preclinical models of human neuroblastoma. Clin Cancer Res. 2017;23(15):4354\u201363.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3411_CR25","doi-asserted-by":"publisher","first-page":"9143","DOI":"10.1038\/s41598-020-65767-7","volume":"10","author":"I Zavrakidis","year":"2020","unstructured":"Zavrakidis I, Jozwiak K, Hauptmann M. Statistical analysis of longitudinal data on tumour growth in mice experiments. Sci Rep. 2020;10(1):9143.","journal-title":"Sci Rep"},{"issue":"33","key":"3411_CR26","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.18632\/oncotarget.27686","volume":"11","author":"GK In","year":"2020","unstructured":"In GK, Poorman K, Saul M, O\u2019Day S, Farma JM, Olszanski AJ, Gordon MS, Thomas JS, Eisenberg B, Flaherty L, et al. Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget. 2020;11(33):3118\u201328.","journal-title":"Oncotarget"},{"issue":"21","key":"3411_CR27","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","volume":"20","author":"G Chen","year":"2014","unstructured":"Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014;20(21):5537\u201346.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"3411_CR28","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.cell.2022.06.007","volume":"185","author":"J Biermann","year":"2022","unstructured":"Biermann J, Melms JC, Amin AD, Wang Y, Caprio LA, Karz A, Tagore S, Barrera I, Ibarra-Arellano MA, Andreatta M, et al. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell. 2022;185(14):2591\u20132608 e2530.","journal-title":"Cell"},{"issue":"1","key":"3411_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s44276-024-00060-y","volume":"2","author":"A Mendoza-Valderrey","year":"2024","unstructured":"Mendoza-Valderrey A, Dettmann E, Hanes D, Kessler DM, Danilova L, Rau K, Quan Y, Stern S, Barkhoudarian G, Bifulco C, et al. Immunogenomics and spatial proteomic mapping highlight distinct neuro-immune architectures in melanoma vs. non-melanoma-derived brain metastasis. BJC Rep. 2024;2(1):38.","journal-title":"BJC Rep"},{"issue":"31","key":"3411_CR30","doi-asserted-by":"publisher","first-page":"e2100178118","DOI":"10.1073\/pnas.2100178118","volume":"118","author":"C Armstrong","year":"2021","unstructured":"Armstrong C, Spencer SL. Replication-dependent histone biosynthesis is coupled to cell-cycle commitment. Proc Natl Acad Sci U S A. 2021;118(31):e2100178118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"3411_CR31","doi-asserted-by":"publisher","first-page":"12469","DOI":"10.1093\/nar\/gku927","volume":"42","author":"M Murillo-Pineda","year":"2014","unstructured":"Murillo-Pineda M, Cabello-Lobato MJ, Clemente-Ruiz M, Monje-Casas F, Prado F. Defective histone supply causes condensin-dependent chromatin alterations, SAC activation and chromosome decatenation impairment. Nucleic Acids Res. 2014;42(20):12469\u201382.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3411_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1083\/jcb.201305017","volume":"204","author":"J Mejlvang","year":"2014","unstructured":"Mejlvang J, Feng Y, Alabert C, Neelsen KJ, Jasencakova Z, Zhao X, Lees M, Sandelin A, Pasero P, Lopes M, et al. New histone supply regulates replication fork speed and PCNA unloading. J Cell Biol. 2014;204(1):29\u201343.","journal-title":"J Cell Biol"},{"issue":"6","key":"3411_CR33","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1083\/jcb.140.6.1285","volume":"140","author":"DA Jackson","year":"1998","unstructured":"Jackson DA, Pombo A. Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells. J Cell Biol. 1998;140(6):1285\u201395.","journal-title":"J Cell Biol"},{"issue":"5","key":"3411_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard H, Garcia-Muse T, Aguilera A. Replication stress and cancer. Nat Rev Cancer. 2015;15(5):276\u201389.","journal-title":"Nat Rev Cancer"},{"issue":"51","key":"3411_CR35","doi-asserted-by":"publisher","first-page":"47759","DOI":"10.1074\/jbc.C100569200","volume":"276","author":"IM Ward","year":"2001","unstructured":"Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem. 2001;276(51):47759\u201362.","journal-title":"J Biol Chem"},{"issue":"13","key":"3411_CR36","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.4161\/cc.5.13.2899","volume":"5","author":"M Downey","year":"2006","unstructured":"Downey M, Durocher D. gammaH2AX as a checkpoint maintenance signal. Cell Cycle. 2006;5(13):1376\u201381.","journal-title":"Cell Cycle"},{"issue":"9","key":"3411_CR37","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1074\/jbc.M806739200","volume":"284","author":"RA Chanoux","year":"2009","unstructured":"Chanoux RA, Yin B, Urtishak KA, Asare A, Bassing CH, Brown EJ. ATR and H2AX cooperate in maintaining genome stability under replication stress. J Biol Chem. 2009;284(9):5994\u20136003.","journal-title":"J Biol Chem"},{"issue":"1","key":"3411_CR38","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/s41467-020-16936-9","volume":"11","author":"K Miao","year":"2020","unstructured":"Miao K, Lei JH, Valecha MV, Zhang A, Xu J, Wang L, Lyu X, Chen S, Miao Z, Zhang X, et al. NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation. Nat Commun. 2020;11(1):3256.","journal-title":"Nat Commun"},{"issue":"1","key":"3411_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13062-021-00313-7","volume":"16","author":"EV Sazonova","year":"2021","unstructured":"Sazonova EV, Petrichuk SV, Kopeina GS, Zhivotovsky B. A link between mitotic defects and mitotic catastrophe: detection and cell fate. Biol Direct. 2021;16(1):25.","journal-title":"Biol Direct"},{"issue":"1","key":"3411_CR40","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1038\/s41467-019-12255-w","volume":"10","author":"VP Masamsetti","year":"2019","unstructured":"Masamsetti VP, Low RRJ, Mak KS, O\u2019Connor A, Riffkin CD, Lamm N, Crabbe L, Karlseder J, Huang DCS, Hayashi MT, et al. Replication stress induces mitotic death through parallel pathways regulated by WAPL and telomere deprotection. Nat Commun. 2019;10(1):4224.","journal-title":"Nat Commun"},{"issue":"3","key":"3411_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/cdd.2008.182","volume":"16","author":"GH Ha","year":"2009","unstructured":"Ha GH, Kim HS, Lee CG, Park HY, Kim EJ, Shin HJ, Lee JC, Lee KW, Lee CW. Mitotic catastrophe is the predominant response to histone acetyltransferase depletion. Cell Death Differ. 2009;16(3):483\u201397.","journal-title":"Cell Death Differ"},{"issue":"7","key":"3411_CR42","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/biom12070904","volume":"12","author":"G Spinozzi","year":"2022","unstructured":"Spinozzi G, Tini V, Ferrari A, Gionfriddo I, Ranieri R, Milano F, Pierangeli S, Donnini S, Mezzasoma F, Silvestri S, et al. SiCoDEA: a simple, fast and complete app for analyzing the effect of individual drugs and their combinations. Biomolecules. 2022;12(7):904.","journal-title":"Biomolecules"},{"key":"3411_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105106","volume":"142","author":"O Campagne","year":"2020","unstructured":"Campagne O, Davis A, Maharaj AR, Zhong B, Stripay J, Farmer D, Roussel MF, Stewart CF. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model. Eur J Pharm Sci. 2020;142: 105106.","journal-title":"Eur J Pharm Sci"},{"issue":"17","key":"3411_CR44","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1158\/1078-0432.CCR-19-4110","volume":"26","author":"G Rao","year":"2020","unstructured":"Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, Zamler D, Doucette TA, Yang Y, Kong LY, et al. Anti-PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells. Clin Cancer Res. 2020;26(17):4699\u2013712.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3411_CR45","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","volume":"82","author":"S Saxena","year":"2022","unstructured":"Saxena S, Zou L. Hallmarks of DNA replication stress. Mol Cell. 2022;82(12):2298\u2013314.","journal-title":"Mol Cell"},{"key":"3411_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.838637","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wu L, Wang Z, Wang J, Roychoudhury S, Tomasik B, Wu G, Wang G, Rao X, Zhou R. Replication stress: a review of novel targets to enhance radiosensitivity-from bench to clinic. Front Oncol. 2022;12: 838637.","journal-title":"Front Oncol"},{"issue":"9","key":"3411_CR47","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/genes11090990","volume":"11","author":"H Zhu","year":"2020","unstructured":"Zhu H, Swami U, Preet R, Zhang J. Harnessing DNA replication stress for novel cancer therapy. Genes (Basel). 2020;11(9):990.","journal-title":"Genes (Basel)"},{"issue":"10","key":"3411_CR48","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","volume":"7","author":"NYL Ngoi","year":"2021","unstructured":"Ngoi NYL, Pham MM, Tan DSP, Yap TA. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends Cancer. 2021;7(10):930\u201357.","journal-title":"Trends Cancer"},{"issue":"1","key":"3411_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41392-020-00358-6","volume":"5","author":"S Li","year":"2020","unstructured":"Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, Ma D, Cai X, Chen M. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduct Target Ther. 2020;5(1):241.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03411-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:05:56Z","timestamp":1748405156000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03411-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3411"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03411-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}